AnaptysBio Inc
ANAB
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.5B
Close$
$-14.56
126.5% downside
Current Fair Value
126.5% downsideOvervalued by 126.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.50 Billion |
|---|---|
| Enterprise Value | $2.53 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.46 |
| Beta | 0.38 |
| Outstanding Shares | 28,691,000 |
Return
| Return on Equity | -210.14% |
|---|---|
| Return on Assets | -8.13% |
| Return on Invested Capital | 10.96% |
Valuation & Multiples
| P/E Ratio | -68.24 |
|---|---|
| PEG | -197.98 |
| Price to Sales | 6.86 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 10.89 |
| Enterprise Value to EBIT | 80.17 |
| Enterprise Value to Net Income | -95 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | 21.76 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 12, 2026
EPS Estimate
$-0.32
Average shareholder expectationRevenue Estimate
$18.86 M
Average shareholder expectationNext Earnings Call
Expected Date
August 5, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
$17.33 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 21.51% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.37%▼ 152.04% |
|---|---|
| Total Invested | $7.15M▼ 99.54% |
| Investors Holding | 14▼ 196.00% |
ESG Score
No data
About AnaptysBio Inc
CEO: Hamza Suria